Differentially expressed microRNAs in the serum of cervical squamous cell carcinoma patients before and after surgery

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Wang, Wen Tao ^a   Zhao, Ya Nan ^a   Yan, Jin Xing ^a   Weng, Mei Ying ^a   Wang, Yan ^b   Chen, Yue Qin ^a   Hong, Shun Jia ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b HAINAN GENERAL HOSPITAL   (China)

Author keywords

Cervical SCC; Circulating microRNA; Post therapeutic monitoring; Serum; Tumor biomarkers

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; MICRORNA; MICRORNA 141; MICRORNA 143 3P; MICRORNA 15A; MICRORNA 181C; MICRORNA 200A 3P; MICRORNA 21 5P; MICRORNA 370; MICRORNA 542 3P; MICRORNA 646; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; FEMALE; GENETIC SCREENING; HUMAN; HUMAN TISSUE; MIDDLE AGED; PATIENT MONITORING; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UPREGULATION; UTERINE CERVIX CARCINOMA;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84892420266     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-7-6     Document Type: Article

References (41)

1. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N, J Pathol 1999 189 1 12 19 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F 10451482 (Pubitemid 29406813)
2. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJ, et al. J Natl Cancer Inst 2006 98 5 303 315 10.1093/jnci/djj067 16507827 (Pubitemid 43338210)
3. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, Naghavi M, Lancet 2011 378 9801 1461 1484 10.1016/S0140-6736(11) 61351-2 21924486
4. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, Int J Cancer 2010 127 12 2893 2917 10.1002/ijc.25516 21351269
5. MicroRNAs: genomics, biogenesis, mechanism, and function. Bartel DP, Cell 2004 116 281 297 10.1016/S0092-8674(04)00045-5 14744438 (Pubitemid 38167318)
6. Long non-coding RNA: a new player in cancer. Zhang H, Chen Z, Wang X, Huang Z, He Z, Chen Y, J Hematol Oncol 2013 6 37 10.1186/1756-8722-6-37 23725405
7. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y, Takahashi T, Cancer Res 2005 65 21 9628 9632 10.1158/0008-5472.CAN-05-2352 16266980 (Pubitemid 41541436)
8. Recent updates on the role of microRNAs in prostate cancer. Hassan O, Ahmad A, Sethi S, Sarkar FH, J Hematol Oncol 2012 5 9 10.1186/1756-8722-5-9 22417299
9. Role of anti-oncomirs miR-143 and -145 in human colorectal tumors. Akao Y, Nakagawa Y, Hirata I, Iio A, Itoh T, Kojima K, Nakashima R, Kitade Y, Naoe T, Cancer Gene Ther 2010 17 6 398 408 10.1038/cgt.2009.88 20094072
10. Diverse functions of miR-125 family in different cell contexts. Sun YM, Lin KY, Chen YQ, J Hematol Oncol 2013 6 6 10.1186/1756-8722-6-6 23321005
11. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP, Khan SA, Oncogene 2008 27 18 2575 2582 10.1038/sj.onc.1210919 17998940 (Pubitemid 351550884)
12. Circulating microRNAs as stable blood-based markers for cancer detection. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al. Proc Natl Acad Sci U S A 2008 105 30 10513 10518 10.1073/pnas.0804549105 18663219
13. High resolution of microRNA signatures in human whole saliva. Patel RS, Jakymiw A, Yao B, Pauley BA, Carcamo WC, Katz J, Cheng JQ, Chan EK, Arch Oral Biol 2011 56 12 1506 1513 10.1016/j.archoralbio.2011.05.015 21704302
14. Expression of microRNAs in the urine of patients with bladder cancer. Wang G, Chan ES, Kwan BC, Li PK, Yip SK, Szeto CC, Ng CF, Clin Genitourin Cancer 2012 10 2 106 113 10.1016/j.clgc.2012.01.001 22386240
15. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Roth C, Rack B, Muller V, Janni W, Pantel K, Schwarzenbach H, Breast Cancer Res 2010 12 6 90 10.1186/bcr2766 21047409
16. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X, Int J Cancer 2010 127 1 118 126 10.1002/ijc.25007 19876917
17. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ, Ann Surg 2010 251 3 499 505 10.1097/SLA.0b013e3181cc939f 20134314
18. Prognostic significance of miR-194 in endometrial cancer. Zhai H, Karaayvaz M, Dong P, Sakuragi N, Ju J, Biomark Res 2013 1 12 10.1186/2050-7771-1-12 24040515
19. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C, Shen H, J Clin Oncol 2010 28 10 1721 1726 10.1200/JCO.2009.24.9342 20194856
20. Circulating microRNAs identified in a genome-wide serum microRNA expression analysis as noninvasive biomarkers for endometriosis. Wang WT, Zhao YN, Han BW, Hong SJ, Chen YQ, J Clin Endocrinol Metab 2013 98 1 281 289 10.1210/jc.2012-2415 23118427
21. Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion. Yu J, Wang Y, Dong R, Huang X, Ding S, Qiu H, J Cancer Res Clin Oncol 2012 138 4 671 674 10.1007/s00432-012-1147-9 22237456
22. Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. Chen J, Yao D, Li Y, Chen H, He C, Ding N, Lu Y, Ou T, Zhao S, Li L, Long F, Int J Mol Med 2013 32 3 557 567 23799609
23. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Zhang Y, Jia Y, Zheng R, Guo Y, Wang Y, Guo H, Fei M, Sun S, Clin Chem 2010 56 12 1830 1838 10.1373/clinchem.2010.147850 20930130
24. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Kuwabara Y, Ono K, Horie T, Nishi H, Nagao K, Kinoshita M, Watanabe S, Baba O, Kojima Y, Shizuta S, et al. Circ Cardiovasc Genet 2011 4 4 446 454 10.1161/CIRCGENETICS.110.958975 21642241
25. Expression of mir-21 and mir-143 in cervical specimens ranging from histologically normal through to invasive cervical cancer. Deftereos G, Corrie SR, Feng Q, Morihara J, Stern J, Hawes SE, Kiviat NB, PLoS One 2011 6 12 28423 10.1371/journal.pone.0028423 22194833
26. Plexin-B1 is a target of miR-214 in cervical cancer and promotes the growth and invasion of HeLa cells. Qiang R, Wang F, Shi LY, Liu M, Chen S, Wan HY, Li YX, Li X, Gao SY, Sun BC, Tang H, Int J Biochem Cell Biol 2011 43 4 632 641 10.1016/j.biocel.2011.01.002 21216304
27. starBase: a database for exploring microRNA-mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data. Yang JH, Li JH, Shao P, Zhou H, Chen YQ, Qu LH, Nucleic Acids Res 2011 39 202 D209 10.1093/nar/gkq1056 21037263
28. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Dennis GJ, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA, Genome Biol 2003 4 5 3 10.1186/gb-2003-4-5-p3
29. Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R, Grohe C, J Biol Chem 2000 275 24 18447 18453 10.1074/jbc.M910345199 10749889 (Pubitemid 30414803)
30. Effect of estrogen and inhibition of phosphatidylinositol-3 kinase on Akt and FOXO1 in rat uterus. Lengyel F, Vertes Z, Kovacs KA, Kornyei JL, Sumegi B, Vertes M, Steroids 2007 72 5 422 428 10.1016/j.steroids.2007.03.001 17433823 (Pubitemid 46602479)
31. Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Brake T, Lambert PF, Proc Natl Acad Sci U S A 2005 102 7 2490 2495 10.1073/pnas. 0409883102 15699322 (Pubitemid 40279404)
32. Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy. Josson S, Anderson CS, Sung SY, Johnstone PA, Kubo H, Hsieh CL, Arnold R, Gururajan M, Yates C, Chung LW, Prostate 2011 71 3 232 240 10.1002/pros.21237 20672324
33. Expression of ADAM9 in CIN3 lesions and squamous cell carcinomas of the cervix. Zubel A, Flechtenmacher C, Edler L, Alonso A, Gynecol Oncol 2009 114 2 332 336 10.1016/j.ygyno.2009.05.005 19473694
34. Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings. Abdel-Fatah TM, Perry C, Dickinson P, Ball G, Moseley P, Madhusudan S, Ellis IO, Chan SY, Ann Oncol 2013 24 11 2801 2807 10.1093/annonc/mdt277 23908177
35. Molecular profiling of cervical cancer progression. Hagemann T, Bozanovic T, Hooper S, Ljubic A, Slettenaar VI, Wilson JL, Singh N, Gayther SA, Shepherd JH, Van Trappen PO, Br J Cancer 2007 96 2 321 328 10.1038/sj.bjc.6603543 17242701 (Pubitemid 46160638)
36. Use of serum squamous cell carcinoma antigen for follow-up monitoring of cervical cancer patients who were treated by concurrent chemoradiotherapy. Yoon SM, Shin KH, Kim JY, Seo SS, Park SY, Moon SH, Cho KH, Radiat Oncol 2010 5 78 10.1186/1748-717X-5-78 20840788
37. Serum CA 125 is an independent prognostic factor in cervical adenocarcinoma. Bender DP, Sorosky JI, Buller RE, Sood AK, Am J Obstet Gynecol 2003 189 1 113 117 10.1067/mob.2003.443 12861147 (Pubitemid 36886533)
38. Serum VEGF levels in patients undergoing primary radiotherapy for cervical cancer: impact on progression-free survival. Bachtiary B, Selzer E, Knocke TH, Potter R, Obermair A, Cancer Lett 2002 179 2 197 203 10.1016/S0304-3835(01)00872-2 11888674 (Pubitemid 34215111)
39. Cervical cancer screening: what's new and what's coming? Jin XW, Lipold L, McKenzie M, Sikon A, Cleve Clin J Med 2013 80 3 153 160 10.3949/ccjm.80a. 12092 23456465
40. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ, Gut 2009 58 10 1375 1381 10.1136/gut.2008.167817 19201770
41. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. Qi P, Cheng SQ, Wang H, Li N, Chen YF, Gao CF, PLoS One 2011 6 12 28486 10.1371/journal.pone.0028486 22174818